Reference number : GC-2017-Q1-00253, amendment number : , agreement type : G, recipient legal name : Kamen, Amine (McGill University)|Kamen, Amine (Université McGill), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : Over the last decades, significant investments have been directed by the US Department of_x000D_
Health and other national and international authorities to build capacities and implement_x000D_
preparedness plans to face influenza pandemic situations. During influenza pandemic,_x000D_
countries have increased vaccine demand for their own population and it is critical to have_x000D_
rapid availability of matched vaccines. However, it may be highly problematic to meet the_x000D_
expected vaccine demand with current egg-based manufacturing process, for instance in the_x000D_
case of an avian pandemic strain that could potentially disrupt the supply chain of eggs._x000D_
Therefore, alternative production processes, including cell culture and plant-based production_x000D_
platforms using recombinant technology, have been developed and validated following_x000D_
recommendations from National and International Health authorities to develop alternative_x000D_
and complementary technologies for rapid and effective responses in emergency situations._x000D_
Currently in Canada, influenza vaccine production is carried out by only one manufacturer_x000D_
using egg-based production technology. Although plant-based process and production_x000D_
capacities are currently being developed by Medicago, for a solid and sustain preparedness_x000D_
plan to face influenza potential pandemics and other emerging infectious disease, it is highly_x000D_
strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case_x000D_
in the US. Taking advantages of advanced technologies recently developed in the applicants_x000D_
laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim_x000D_
to accelerate and intensify, by addressing the limitations at all process steps, the_x000D_
development and validation of a cell-culture production platform for pandemic influenza_x000D_
vaccines as a national alternative and complementary vaccines source., program purpose french : Over the last decades, significant investments have been directed by the US Department of_x000D_
Health and other national and international authorities to build capacities and implement_x000D_
preparedness plans to face influenza pandemic situations. During influenza pandemic,_x000D_
countries have increased vaccine demand for their own population and it is critical to have_x000D_
rapid availability of matched vaccines. However, it may be highly problematic to meet the_x000D_
expected vaccine demand with current egg-based manufacturing process, for instance in the_x000D_
case of an avian pandemic strain that could potentially disrupt the supply chain of eggs._x000D_
Therefore, alternative production processes, including cell culture and plant-based production_x000D_
platforms using recombinant technology, have been developed and validated following_x000D_
recommendations from National and International Health authorities to develop alternative_x000D_
and complementary technologies for rapid and effective responses in emergency situations._x000D_
Currently in Canada, influenza vaccine production is carried out by only one manufacturer_x000D_
using egg-based production technology. Although plant-based process and production_x000D_
capacities are currently being developed by Medicago, for a solid and sustain preparedness_x000D_
plan to face influenza potential pandemics and other emerging infectious disease, it is highly_x000D_
strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case_x000D_
in the US. Taking advantages of advanced technologies recently developed in the applicants_x000D_
laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim_x000D_
to accelerate and intensify, by addressing the limitations at all process steps, the_x000D_
development and validation of a cell-culture production platform for pandemic influenza_x000D_
vaccines as a national alternative and complementary vaccines source., agreement title english : Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation, agreement title french : Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation, agreement number : CHRPJ, agreement value : 371615.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada